Our mission is to discover treatments and a cure for ALS, and to serve, advocate for, and empower people affected by ALS to live their lives to the fullest.
The Lawrence and Isabel Barnett Drug Development Program is designed to accelerate the development of new, effective ALS treatments. It focuses on supporting the preclinical assessment of novel therapies or repositioned treatment approaches to prepare for clinical testing. This program offers 2-year awards with a budget up to $500,000, open to industry and academic investigators. Applicants must have a development candidate ready, aiming to push programs with a high probability of entering clinical trials within 3 years. Priority is given to applications with strong data supporting the treatment's biological rationale, a detailed development plan including critical decision milestones, and a focus on pharmacokinetic and pharmacodynamic relationships, along with necessary studies such as in vivo efficacy testing, preclinical toxicology, and other IND-enabling studies.